Back to Journals » Therapeutics and Clinical Risk Management » Volume 13

High expression of Aldolase A predicts poor survival in patients with clear-cell renal cell carcinoma

Authors Na N, Li H, Xu CF, Miao B, Hong LQ, Huang ZY, Jiang Q

Received 26 September 2016

Accepted for publication 21 November 2016

Published 27 February 2017 Volume 2017:13 Pages 279—285


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Deyun Wang

Ning Na,1,* Heng Li,1,* Chengfang Xu,2,* Bin Miao,1 Liangqing Hong,1 Zhengyu Huang,1 Qiu Jiang3

1Department of Kidney Transplantation, 2Department of Obstetrics and Genecology, The Third Affiliated Hospital of Sun Yat-sen University, 3Department of Organ Transplantation, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, People’s Republic of China

*These authors contributed equally to this work

Background: Aldolase A (ALDOA) is a glycolytic enzyme that drives the glycolytic metabolic pathway in mammalian cells. The overexpression of ALDOA was observed in a variety of cancers including clear-cell renal cell carcinoma (ccRCC). However, little was known about the clinicopathological significance and prognostic value of ALDOA in ccRCC patients.
Methods: The expression of ALDOA was detected using immunohistochemical staining in 162 formalin-fixed, paraffin-embedded ccRCC sections. Prognostic outcomes correlated with ALDOA were examined using Kaplan–Meier analysis and the Cox proportional hazards model.
Results: In patients with ccRCC, increased cytoplasmic ALDOA expression was positively associated with tumor size (P=0.021), TNM stages (P=0.034), lymph node metastasis (P=0.020), and overall survival (OS) (P<0.001). Kaplan–Meier analysis showed that high cytoplasmic expression of ALDOA was associated with a statistically significant lower OS (P<0.001). Multivariate analysis demonstrated that ALDOA expression was an independent and significant prognostic factor (HR =3.561, 95% CI =1.715–7.396, P=0.001). ALDOA expression was not associated with significant prognostic deference in the subgroups of TNM stage I patients or pT1 patients.
Conclusion: Our results suggest that ALDOA expression is an independent prognostic factor for OS in patients with ccRCC.

Keywords: renal carcinoma, Aldolase A, glycolysis, prognosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]